{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T15:46:06Z","timestamp":1765295166679,"version":"3.37.3"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T00:00:00Z","timestamp":1600387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T00:00:00Z","timestamp":1600387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"JSPS KAKENHI","award":["JP16K19623"],"award-info":[{"award-number":["JP16K19623"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1007\/s10157-020-01970-0","type":"journal-article","created":{"date-parts":[[2020,9,18]],"date-time":"2020-09-18T04:11:44Z","timestamp":1600402304000},"page":"44-51","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Podocyte sphingomyelin phosphodiesterase acid-like 3b decreases among children with idiopathic nephrotic syndrome"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4379-5857","authenticated-orcid":false,"given":"Shojiro","family":"Watanabe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Hirono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomi","family":"Aizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Tsugawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kensuke","family":"Joh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadaatsu","family":"Imaizumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,18]]},"reference":[{"key":"1970_CR1","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/S0140-6736(14)60541-9","volume":"384","author":"K Iijima","year":"2014","unstructured":"Iijima K, Sako M, Nozu K, et al. Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2014;384:1273\u201381.","journal-title":"Lancet"},{"key":"1970_CR2","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s10157-016-1313-5","volume":"21","author":"K Iijima","year":"2017","unstructured":"Iijima K, Sako M, Nozu K. Rituximab for nephrotic syndrome in children. Clin Exp Nephrol. 2017;21:193\u2013202.","journal-title":"Clin Exp Nephrol"},{"key":"1970_CR3","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s00467-012-2319-1","volume":"28","author":"S Ito","year":"2013","unstructured":"Ito S, Kamei K, Ogura M, et al. Survey of rituximab treatment for childhood-onset refractory nephrotic syndrome. Pediatr Nephrol. 2013;28:257\u201364.","journal-title":"Pediatr Nephrol"},{"key":"1970_CR4","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s10157-017-1415-8","volume":"22","author":"M Sato","year":"2018","unstructured":"Sato M, Kamei K, Ogura M, Ishikura K, Ito S. Relapse of nephrotic syndrome during post-rituximab peripheral blood B-lymphocyte depletion. Clin Exp Nephrol. 2018;22:110\u20136.","journal-title":"Clin Exp Nephrol"},{"key":"1970_CR5","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1182\/blood-2005-04-1769","volume":"107","author":"F Perosa","year":"2006","unstructured":"Perosa F, Favoino E, Caragnano MA, Dammacco F. Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor. Blood. 2006;107:1070\u20137.","journal-title":"Blood"},{"issue":"85","key":"1970_CR6","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1126\/scitranslmed.3002231","volume":"3","author":"A Fornoni","year":"2011","unstructured":"Fornoni A, Sageshima J, Wei C, et al. Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis. Sci Transl Med. 2011;3(85):85\u201346 (85ra46).","journal-title":"Sci Transl Med"},{"key":"1970_CR7","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/nep.12737","volume":"22","author":"Y Takahashi","year":"2017","unstructured":"Takahashi Y, Ikezumi Y, Saitoh A. Rituximab protects podocytes and exerts anti-proteinuric effects in rat adriamycin-induced nephropathy independent of B-lymphocytes. Nephrol (Carlton). 2017;22:49\u201357.","journal-title":"Nephrol (Carlton)"},{"key":"1970_CR8","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1096\/fj.201600618R","volume":"31","author":"A Ahmad","year":"2017","unstructured":"Ahmad A, Mitrofanova A, Bielawski J, et al. Sphingomyelinase-like phosphodiesterase 3b mediates radiation-induced damage of renal podocytes. FASEB J. 2017;31:771\u201380.","journal-title":"FASEB J"},{"key":"1970_CR9","first-page":"12","volume":"18","author":"A Abou Daher","year":"2014","unstructured":"Abou Daher A, El Jalkh T, Eid AA, Fornoni A, Marples B, Zeidan YH. Translational aspects of sphingolipid metabolism in renal disorders. Int J Mol Sci. 2014;18:12 (pii: E2528).","journal-title":"Int J Mol Sci"},{"key":"1970_CR10","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3389\/fendo.2014.00127","volume":"5","author":"S Merscher","year":"2014","unstructured":"Merscher S, Fornoni A. Podocyte pathology and nephropathy - sphingolipids in glomerular diseases. Front Endocrinol (Lausanne). 2014;5:127. https:\/\/doi.org\/10.3389\/fendo.2014.00127(eCollection 2014).","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1970_CR11","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1111\/ped.13355","volume":"59","author":"S Watanabe","year":"2017","unstructured":"Watanabe S, Tsugawa K, Tsuruga K, Imaizumi T, Tanaka H. Urinary excretion of sphingomyelinase phosphodiesterase acid-like 3b in children with intractable nephrotic syndrome. Pediatr Int. 2017;59:1112\u20135.","journal-title":"Pediatr Int"},{"issue":"13\u201314","key":"1970_CR12","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1016\/j.clinbiochem.2016.05.001","volume":"49","author":"M Shipkova","year":"2016","unstructured":"Shipkova M, Svinarov D. LC-MS\/MS as a tool for TDM services: where are we? Clin Biochem. 2016;49(13\u201314):1009\u2013233.","journal-title":"Clin Biochem"},{"issue":"3","key":"1970_CR13","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1002\/mas.20264","volume":"29","author":"MM Kushnir","year":"2010","unstructured":"Kushnir MM, Rockwood AL, Bergquist J. Liquid chromatography-tandem mass spectrometry applications in endocrinology. Mass Spectrom Rev. 2010;29(3):480\u2013502.","journal-title":"Mass Spectrom Rev"},{"key":"1970_CR14","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.cca.2018.11.001","volume":"488","author":"G Forni","year":"2019","unstructured":"Forni G, Malvagia S, Funghini S, et al. LC-MS\/MS method for simultaneous quantification of heparan sulfate and dermatan sulfate in urine by butanolysis derivatization. Clin Chim Acta. 2019;488:98\u2013103.","journal-title":"Clin Chim Acta"},{"key":"1970_CR15","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1159\/000013302","volume":"18","author":"M Hara","year":"1998","unstructured":"Hara M, Yanagihara T, Takada T, et al. Urinary excretion of podocytes reflects disease activity in children with glomerulonephritis. Am J Nephrol. 1998;18:35\u201341.","journal-title":"Am J Nephrol"},{"key":"1970_CR16","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1177\/1535370214548995","volume":"240","author":"P Wang","year":"2015","unstructured":"Wang P, Li M, Liu Q, et al. Detection of urinary podocytes and nephrin as markers for children with glomerular diseases. Exp Biol Med. 2015;240:169\u201374. https:\/\/doi.org\/10.1177\/1535370214548995.","journal-title":"Exp Biol Med"},{"key":"1970_CR17","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.bbamcr.2005.09.001","volume":"1746","author":"CR Bollinger","year":"2005","unstructured":"Bollinger CR, Teichgr\u00e4ber V, Gulbins E. Ceramide-enriched membrane domains. Biochim Biophys Acta. 2005;1746:284\u201394.","journal-title":"Biochim Biophys Acta"},{"key":"1970_CR18","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1016\/j.celrep.2015.05.006","volume":"11","author":"LX Heinz","year":"2015","unstructured":"Heinz LX, Baumann CL, K\u00f6berlin MS, et al. The lipid-modifying enzyme SMPDL3B negatively regulates innate immunity. Cell Rep. 2015;11:1919\u201328. https:\/\/doi.org\/10.1016\/j.celrep.2015.05.006.","journal-title":"Cell Rep"},{"key":"1970_CR19","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s12079-012-0184-0","volume":"7","author":"T Srivastava","year":"2013","unstructured":"Srivastava T, Sharma M, Yew KH, et al. LPS and PAN-induced podocyte injury in an in vitro model of minimal change disease: changes in TLR profile. J Cell Commun Signal. 2013;7:49\u201360.","journal-title":"J Cell Commun Signal"},{"key":"1970_CR20","doi-asserted-by":"publisher","first-page":"22579","DOI":"10.1038\/srep22579","volume":"6","author":"W Bao","year":"2016","unstructured":"Bao W, Xia H, Liang Y, et al. Toll-like receptor 9 can be activated by endogenous mitochondrial DNA to induce podocyte apoptosis. Sci Rep. 2016;6:22579. https:\/\/doi.org\/10.1038\/srep22579.","journal-title":"Sci Rep"},{"key":"1970_CR21","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1681\/ASN.2013111213","volume":"26","author":"TH Yoo","year":"2015","unstructured":"Yoo TH, Pedigo CE, Guzman J, et al. Sphingomyelinase-like phosphodiesterase 3b expression levels determine podocyte injury phenotypes in glomerular disease. J Am Soc Nephrol. 2015;26:133\u201347.","journal-title":"J Am Soc Nephrol"},{"key":"1970_CR22","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1111\/nep.12155","volume":"18","author":"S Watanabe","year":"2013","unstructured":"Watanabe S, Imaizumi T, Tsuruga K, et al. Glomerular expression of myxovirus resistance protein 1 in human mesangial cells: possible activation of innate immunity in the pathogenesis of lupus nephritis. Nephrol (Carlton). 2013;18:833\u20137.","journal-title":"Nephrol (Carlton)"},{"key":"1970_CR23","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s10157-014-1060-4","volume":"19","author":"T Imaizumi","year":"2015","unstructured":"Imaizumi T, Aizawa T, Segawa C, et al. Toll-like receptor 3 signaling contributes to the expression of a neutrophil chemoattractant, CXCL1 in human mesangial cells. Clin Exp Nephrol. 2015;19:761\u201370.","journal-title":"Clin Exp Nephrol"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-020-01970-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-020-01970-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-020-01970-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,18]],"date-time":"2021-09-18T00:08:12Z","timestamp":1631923692000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-020-01970-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,18]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["1970"],"URL":"https:\/\/doi.org\/10.1007\/s10157-020-01970-0","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"type":"print","value":"1342-1751"},{"type":"electronic","value":"1437-7799"}],"subject":[],"published":{"date-parts":[[2020,9,18]]},"assertion":[{"value":"12 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Shojiro Watanabe received research founding from Ono Pharmaceutical Co., Ltd, Japan. The other Drs have no COI to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}